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Abstract
Background: Sevoflurane has been demonstrated to vasodilate the foeto-placental vasculature.
We aimed to determine the contribution of modulation of potassium and calcium channel function
to the vasodilatory effect of sevoflurane in isolated human chorionic plate arterial rings.
Methods: Quadruplicate ex vivo human chorionic plate arterial rings were used in all studies.
Series 1 and 2 examined the role of the K+ channel in sevoflurane-mediated vasodilation. Separate
experiments examined whether tetraethylammonium, which blocks large conductance calcium
activated K+ (KCa++) channels (Series 1A+B) or glibenclamide, which blocks the ATP sensitive K+
(KATP) channel (Series 2), modulated sevoflurane-mediated vasodilation. Series 3 – 5 examined the
role of the Ca++ channel in sevoflurane induced vasodilation. Separate experiments examined
whether verapamil, which blocks the sarcolemmal voltage-operated Ca++ channel (Series 3), SK&F
96365 an inhibitor of sarcolemmal voltage-independent Ca++ channels (Series 4A+B), or ryanodine
an inhibitor of the sarcoplasmic reticulum Ca++ channel (Series 5A+B), modulated sevoflurane-
mediated vasodilation.
Results: Sevoflurane produced dose dependent vasodilatation of chorionic plate arterial rings in
all studies. Prior blockade of the KCa++ and KATP channels augmented the vasodilator effects of
sevoflurane. Furthermore, exposure of rings to sevoflurane in advance of TEA occluded the effects
of TEA. Taken together, these findings suggest that sevoflurane blocks K+ channels. Blockade of the
voltage-operated Ca++channels inhibited the vasodilator effects of sevoflurane. In contrast,
blockade of the voltage-independent and sarcoplasmic reticulum Ca++channels did not alter
sevoflurane vasodilation.
Conclusion: Sevoflurane appears to block chorionic arterial KCa++ and KATP channels. Sevoflurane
also blocks voltage-operated calcium channels, and exerts a net vasodilatory effect in the in vitro
foeto-placental circulation.
Published: 10 June 2009
BMC Anesthesiology 2009, 9:4 doi:10.1186/1471-2253-9-4
Received: 8 December 2008
Accepted: 10 June 2009
This article is available from: http://www.biomedcentral.com/1471-2253/9/4
© 2009 Jarman et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
Page 2 of 11
(page number not for citation purposes)
Background
Sevoflurane has gained widespread acceptance in obstet-
ric anaesthesia [1-3], and has an excellent clinical profile
in this population [2,3]. We have recently demonstrated
that sevoflurane vasodilates the foeto-placental vascula-
ture in vitro, in part by a mechanism that is mediated via
inhibition of lipoxygenase [4]. However, the potential for
sevoflurane to cause vasodilation via modulation of cal-
cium and potassium ion channel function in this circula-
tion remains to be determined.
The potential for volatile anaesthetic agents to modulate
vascular tone via alterations in calcium and potassium ion
channel function in other circulations is clear. Halothane
has been demonstrated to vasodilate conducting and
resistance coronary arteries via activation of the KATP chan-
nel [5]. Sevoflurane-mediated activation of potassium ion
(K+) channels would increase potassium conductance,
causing myocyte hyperpolarisation and vasodilation [6].
Two types of K+ channels of functional importance in the
vasculature are the Ca++-activated K+ (KCa++) channels and
the ATP-sensitive K+ (KATP) channels [6]. The effects of
sevoflurane on to K+ channels appear to be depend on
channel subtype. Sevoflurane has been demonstrated to
selectively increase coronary collateral blood flow via
mechanisms that appear to be independent of KATP chan-
nel activation [7], but which involve activation of KCa++
channels [8].
Sevoflurane could also cause vasodilation via inhibition
of one or more calcium (Ca++) channels. At least three dis-
tinct types of Ca++ channels are of importance in the vas-
culature: the sarcolemmal voltage-operated Ca++ channel
(VOCC) [9]; sarcolemmal voltage-independent Ca++
channels (VICC) [9,10]; and sarcoplasmic reticulum cal-
cium channel. Of interest, halothane has been demon-
strated to activate VICC channel activity, while
sevoflurane did not have any effect on these channels, in
the rat aorta [9].
We therefore hypothesized that sevoflurane would
vasodilate the foeto-placental circulation by a mechanism
involving alterations in the activity of potassium and/or
calcium channels. Specifically, we hypothesized that
sevoflurane activates K+ channels, causing myocyte hyper-
polarisation and vasodilation. Our second hypothesis was
that sevoflurane inhibits Ca++ channels, thereby reducing
intracellular Ca++  concentrations, and thus directly
reduces vessel tension.
Methods
Following ethical committee approval, and written
informed patient consent, term placentae were obtained
after both vaginal and caesarean delivery under neuraxial
anaesthesia from healthy parturients. Exclusion criteria
included pre-existing hypertension, intra-uterine growth
retardation, pre-eclampsia, multiple pregnancies, and
patients with pregnancy induced hypertension, hepatitis
and HIV infection.
All studies followed a randomised, controlled, paired
design. Samples of the second-order chorionic plate arter-
ies were taken within 120 minutes of delivery and placed
directly into ice-cold pyrogen-free physiologic saline solu-
tion. Four chorionic rings, each 3 mm in length, from a
single artery from each placenta, were isolated, mounted
in PSS at 37°C, and equilibrated with 95% O2 – 5% CO2
in tissue baths (10 ml capacity) as previously described
[4,11] (Figure 1). Samples of the solution were intermit-
tently analyzed for PO2, PCO2 and pH. PCO2 was main-
tained in the range 3.5 – 4.5 kPa, and pH was maintained
in the range 7.35 – 7.45 in all experiments. Rings were
threaded onto a horizontally fixed platinum surgical wire
(300 μm diameter). A second hook, connected to an iso-
metric force transducer, was then passed through the
lumen of the ring. Isometric tension was recorded as a
function of time using a transducer system (Grass FT03,
Quincy, MA) (Figure 2).
Schematic representation of the ex vivo incubation model  system used in the isolated vessel experiments Figure 1
Schematic representation of the ex vivo incubation 
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Baseline Interventions
Following a 60 minute equilibration period, an optimal
pre-tension of 2.00 g for each chorionic plate arterial ring
was utilised [4]. Priming contractions were induced by
exposing the rings three times to 80 mM KCl solution
(iso-osmotically substituted for NaCl), and pre-tension
re-established at the end of each 5 minute exposure by
rinsing with physiologic saline solution (Figure 2). The
rings were then submaximally pre-constricted with the
thromboxane analog U46619 (9,11-dideoxy-11α, 9α-
epoxymethanoprostagladin F2α, 5 × 10-6 M). Once a sta-
ble plateau contractile response was obtained, the rings
were allowed to remain at the plateau tension for 30 min-
utes.
K+ Channel Experimental Series
Each experimental series followed a similar overall design
(Figure 2). Series 1 examined the role of the calcium acti-
vated K+ (KCa++) channel in mediating the vasodilatory
effect of sevoflurane. Tetraethylammonium (TEA), which
at lower doses (1 – 3 × 10-2 M), blocks large conductance
calcium activated K+ (KCa++) channels [12-14] was utilised
in these experiments. Series 1A determined whether prior
incubation with TEA modulated the vasodilation pro-
duced by sevoflurane. Following U46619 pre-constric-
tion, two rings from each placenta were randomly
assigned to receive sevoflurane in the perfusing gas, in 2%
increments sequentially attained at 30 minute intervals,
with the remaining two rings serving as controls (Figure
2). TEA (1 × 10-2 M) was first added to one sevoflurane
exposed bath and one control bath, and allowed to equil-
ibrate for 20 minutes, and vehicle added to the remaining
baths. This resulted in four groups: (1) control with vehi-
cle (Control); (2) control with TEA (TEA); (3) sevoflurane
with vehicle (SEVO); (4) sevoflurane with TEA
(SEVO+TEA). Increasing sevoflurane perfusate concentra-
tions from 2% – 8% were then sequentially attained at 30
minute intervals.
Series 1B determined the effect of prior incubation of the
rings with sevoflurane on the vasoactive effect of TEA. Fol-
lowing U46619 pre-constriction and the attainment of a
plateau contraction, two rings were randomly assigned to
receive 8% sevoflurane in the perfusing gas (95% O2 – 5%
CO2) or perfusing gas alone. After 60 minutes, TEA (1 ×
10-2 M) was added to one sevoflurane exposed bath and
one control bath, and vehicle added to the remaining
baths, and the effects measured. Series 2 examined the
role of the ATP sensitive K+ channel (KATP) channel in
mediating the vasodilatory effect of sevoflurane. Gliben-
clamide, which at lower doses (1 × 10-5 M) specifically
blocks the KATP channel [15,16], was utilised in these
experiments. Following U46619 pre-constriction, and the
addition of 1 × 10-5 M glibenclamide or vehicle, rings were
exposed to sevoflurane or vehicle gas alone as described
for series 1A.
Ca++ Channel Experimental Series
Series 3 examined the role of the sarcolemmal voltage-
operated Ca++ channel (VOCC). Following U46619 pre-
constriction, verapamil 1 × 10-6  M, which specifically
blocks the VOCC channel [9,17,18] or vehicle was added,
and the rings exposed to sevoflurane or perfusing gas
alone as described for series 1A. Series 4 examined the role
of the sarcolemmal voltage-independent Ca++ channels
(VICC) [9,10]. SK&F 96365, which at concentrations in
the 10-4 – 10-6 M range specifically blocks the VICC chan-
nel [9,10,19], was utilised in these experiments. Series 4A
examined whether 3 × 10-5  M SK&F 96365 blocked
sevoflurane-mediated vasodilation. Series 4B examined
the effect of higher concentrations of SK&F 96365 (1 × 10-
4 M). Series 5 examined the role of the sarcoplasmic retic-
ulum Ca++ channel [9,10]. Ryanodine, which at concen-
trations of up to 10-4 M specifically inhibits sarcoplasmic
each experimental series, with the exception of series 1B Figure 2
Schematic representation of the experimental design 
used in each experimental series, with the exception 
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reticulum calcium release [20,21] was utilised in these
experiments. Series 5A examined the effect of 5 × 10-6 M
ryanodine, while Series 5B determined whether 5 × 10-5 M
ryanodine attenuated the vasodilation produced by
sevoflurane.
End protocol contractility assessment
At the end of each experiment, sevoflurane was discontin-
ued, and baseline pre-tension re-established. The contrac-
tile response to 80 mM KCl was then reassessed and data
was excluded from the analysis if the maximum final KCl-
induced contraction in control rings was less than 90% of
the initial KCl response.
Determination of bath sevoflurane concentrations
The sevoflurane was introduced into the tissue baths in
the perfusing gas via  a sevoflurane vapouriser (Abbott
Inc., Dublin, Ireland). The vapour content of anaesthetic
agent in the carrier gas was continuously measured by
means of an in-line agent monitor (Datex Capnomac
Ultima®, Helsinki, Finland). The perfusing gas was contin-
uously sampled downstream from the vapouriser, at a
point just proximal to the entry of the gas into the tissue
baths. Volatile anaesthetic concentrations increased
within 10 minutes to within 10% of the value dialled on
the vapouriser in all experiments. In addition, in a sepa-
rate series of experiments, the bath concentrations of
sevoflurane were verified using gas chromatography-mass
spectrometry, for sevoflurane concentrations in the per-
fused gas of 0 – 8%, as previously described [4].
Chemicals
U46619, tetraethylammonium (TEA)α, glibenclamide,
verapamil, SK & F 96365, sodium nitroprusside, and all
salts were all purchased from Sigma Aldrich (Poole, Dor-
set, U.K.). Ryanodine was purchased from BIOMOL Inter-
national L.P. (Exeter, Devon, U.K.). Sevoflurane was
purchased from Abbott Inc. (Dublin, Ireland).
Statistical Analysis
Data are presented as means ± SD with vasodilation by
sevoflurane expressed as a percentage of the submaximal
contraction elicited with U46619. The EC50r value, which
represents the concentration of sevoflurane required
dilate the pre-constricted rings by 50%, was calculated for
each ring, in each experimental series. Firstly, the slope
and intercept of the line connecting the sevoflurane values
immediately below and above 50% was determined. The
EC50r value is calculated by the following formula: EC50r =
10X  where X = (50 – Intercept)/Slope. Comparison
between control and test rings was made using two way
repeated measures analysis of variance, with group as a
between subjects factor and percentage sevoflurane as a
repeated measures factor. Between group analyses were
restricted to comparisons relevant to our a priori hypothe-
ses, and were made using Student's t testing with correc-
tions for multiple comparisons. The null hypothesis was
rejected for p < 0.05.
Results
Chorionic plate arterial rings were obtained from 80 pla-
centae from women ((median age, 26 years [range, 18–43
years]; median parity, 1 [range, 0–4]) following uncom-
plicated full term (median gestation 40 wks [range 38–
41]) gestation, for these studies. Stable and comparable
gas tensions were maintained throughout all experiments,
and comparable baseline levels of contractile responses
were observed in all series. Post-intervention responses to
potassium chloride were not different compared to base-
line for any rings studied, and therefore no rings were
excluded.
Sevoflurane and the K+ Channel
In Series 1A, blockade of the calcium activated K+ (KCa++)
channel (n = 10 rings per group) with 1 × 10-2 M TEA sig-
nificantly increased sevoflurane-mediated vasodilation
compared to sevoflurane alone (Figure 3). TEA pre-treat-
ment significantly decreased the EC50r for sevoflurane (6.2
± 0.8% versus 7.5 ± 0.7%, P < 0.01). In series 1B (n = 10
rings per group), 1 × 10-2 M TEA caused marked but tran-
sient vasoconstriction, with a maximal contraction of 36.5
± 3.1% attained 8 minutes following TEA addition (Figure
4). Prior incubation of rings with sevoflurane abolished
the vasoconstrictor effect of TEA. This suggests that
sevoflurane directly blocks the KCa++  channel, thereby
occluding the effect of TEA.
In  Series 2, blockade of the ATP sensitive K+ channel
(KATP) channel (n = 10 rings per group) with 1 × 10-5 M
glibenclamide significantly increased sevoflurane-medi-
ated vasodilation compared to sevoflurane alone (Figure
5). Glibenclamide pre-treatment significantly decreased
the EC50r for sevoflurane (5.5 ± 0.9% versus 6.8 ± 1.0%, P
< 0.005).
Sevoflurane and the Ca++ Channel
In Series 3, blockade of the sarcolemmal voltage-operated
Ca++ channel (n = 10 rings per group) with 1 × 10-6 M ver-
apamil significantly inhibited sevoflurane-mediated
vasodilation compared to sevoflurane alone (Figure 6).
Verapamil pre-treatment significantly increased the EC50r
for sevoflurane (9.8 ± 1.1% versus 6.7 ± 1.0%, P < 0.01).
In Series 4A, blockade of the sarcolemmal voltage-inde-
pendent Ca++ channel with 3 × 10-5 M SK&F 96365 (n = 10
rings per group) did not alter sevoflurane-mediated
vasodilation (data not presented). In Series 4B, higher
concentrations (1 × 10-4 M) of SK&F 96365 (n = 10 rings
per group) were similarly ineffective in altering sevoflu-BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
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rane-mediated vasodilation. (Figure 7), and did not alter
the EC50r for sevoflurane (6.7 ± 0.9% versus 6.9 ± 1.0%, P
= 0.7).
In Series 5A, blockade of the sarcoplasmic reticulum Ca++
channel with 5 × 10-6 M ryanodine (n = 10 rings per
group) did not alter sevoflurane-mediated vasodilation
(data not presented). In Series 5B, higher concentrations
(5 × 10-5 M) of ryanodine (n = 10 rings per group) were
similarly ineffective in altering sevoflurane-mediated
vasodilation. (Figure 8), and did not alter the EC50r for
sevoflurane (6.7 ± 1.0% versus 6.8 ± 0.9%, P = 0.8).
Discussion
A substantial number of patients require general anaesthe-
sia during pregnancy, for a variety of indications, includ-
ing non-obstetric surgery [22]. In fact, the need for general
anaesthesia during pregnancy may increase in future
years, due to the emergence of in utero foetal surgical tech-
niques, such as the ex utero intrapartum treatment (EXIT)
procedure [23]. These procedures generally employ higher
sevoflurane concentrations in order to produce uterine
relaxation and facilitate in utero surgery, with concentra-
tions of 4 – 5% sevoflurane reported for the EXIT proce-
dure [24].
We have recently demonstrated that sevoflurane produces
dose dependent vasodilation in the foeto-placental circu-
lation in vitro [4]. These effects of sevoflurane are medi-
ated via a mechanism that is NO-independent and which
was mediated in part via the generation of lipoxygenase
derived vasodilator prostanoids. However, blockade of
the lipoxygenase enzyme does not abolish sevoflurane-
mediated vasodilation, suggesting that other mechanisms
Blockade of KCa++ channels enhances the vasodilatory effect of sevoflurane Figure 3
Blockade of KCa++ channels enhances the vasodilatory effect of sevoflurane. Sevoflurane produced significant dose 
dependent vasodilation of chorionic plate arterial rings compared to control conditions. Prior blockade of KCa++ channels by 
incubation in 1 × 10-2 M tetraethylammonium (n = 10 rings per group) enhanced the vasodilatory effect of sevoflurane. *P < 
0.05 compared to rings exposed to control conditions. (Two way RM-ANOVA). † P < 0.05 compared to rings exposed to 
sevoflurane plus vehicle at graded sevoflurane concentrations (post hoc between group t test).BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
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of action may contribute to this effect. One potential
mechanism by which sevoflurane may produce vasodila-
tion in this circulation would be via the modulation of ion
channel function. The effects of volatile anaesthetic agents
on K+ channels appear to be agent and vascular bed spe-
cific. Halothane-mediated vasodilation of conducting and
resistance coronary arteries is mediated via activation of
the adenosine triphosphate-sensitive potassium (KATP)
channels [5]. In contrast, sevoflurane increases coronary
collateral blood flow via mechanisms that appear to be
independent of KATP channel activation [7], but which
involve activation of KCa++ channels [8]. These findings
lead us to hypothesize that sevoflurane may produce
vasodilation in the foeto-placental circulation via activa-
tion of KCa++ and/or KATP channels.
Our findings demonstrate that sevoflurane did not pro-
duce vasodilation via activation of either the KCa++ or the
KATP channel. In fact, prior exposure of the chorionic arte-
rial rings to TEA, which blocks the KCa++ channels, and
glibenclamide, which blocks the KATP  channel, clearly
enhanced sevoflurane-mediated vasodilation. This sug-
gests that sevoflurane in part inhibited or blocked these K+
channels, contrary to our contention. We wished to con-
firm that sevoflurane did indeed block the KCa++ and KATP
channels. If this contention were correct, then prior incu-
bation of the rings with sevoflurane would prevent bind-
ing of agents that block these channels, and thereby
abolish their effect. In further experiments, carried out to
clarify this issue, blockade of KCa++  channels by TEA
caused transient vasoconstriction, which demonstrates a
role for the KCa++ channels in regulating vasomotor tone in
the foeto-placental circulation. However, prior incubation
of the rings with sevoflurane prior to exposure to TEA
abolished this effect. Taken together, these findings indi-
cate that sevoflurane blocks the KCa++ channel. These find-
Prior exposure of chorionic rings to sevoflurane blocks the effect of tetraethylammonium Figure 4
Prior exposure of chorionic rings to sevoflurane blocks the effect of tetraethylammonium. Exposure of rings to 1 
× 10-2 M tetraethylammonium transiently enhances resting tone. This effect is abolished following prior incubation in sevoflu-
rane, demonstrating that sevoflurane blocks KCa++ channels (n = 10 rings per group). *P < 0.05 compared to control (Two way 
RM-ANOVA). † P < 0.05 compared to control at each timepoint (post hoc between group t test).BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
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ings are not inconsistent with previous literature.
Halothane has been demonstrated to depress the function
of a wide variety of both invertebrate and mammalian K+
channels [25], including the KCa++ channel in rodents
[26], and in canine cerebral and coronary vascular smooth
muscle [27]. Our findings emphasise the potential for vol-
atile anaesthetic agent to exert effects on vascular bed spe-
cific the KCa++ or the KATP channel.
Our second hypothesis was that sevoflurane produced
vasorelaxation in part via  the blockade of calcium ion
channels. We therefore examined the potential for the
effects of sevoflurane to be mediated via the sarcolemmal
voltage-operated Ca++ channel (VOCC) [9], the sarcolem-
mal voltage-independent Ca++ channels (VICC) [9,10],
and/or the sarcoplasmic reticulum calcium channel. Our
findings demonstrate that sevoflurane produced vasodila-
tion, at least in part, via an effect on the sarcolemmal volt-
age-operated calcium channel (VOCC). Prior incubation
with the VOCC channel blocker verapamil, at concentra-
tions similar to that previously reported [17,18], signifi-
cantly inhibited sevoflurane-mediated vasodilation of the
pre-constricted chorionic plate arterial rings. These find-
ings demonstrate that sevoflurane-mediated vasodilation
in this circulation is dependent in part on a blocking effect
at the VOCC channel. This effect of sevoflurane would
reduce intracellular calcium influx, and thereby reduce
chorionic plate arterial vasomotor tone. In contrast, the
vasomotor effects of sevoflurane appear to be independ-
ent of both the sarcolemmal voltage-independent calcium
channel and alterations in sarcoplasmic reticulum cal-
cium release.
Blockade of KATP channels enhances the vasodilatory effect of sevoflurane Figure 5
Blockade of KATP channels enhances the vasodilatory effect of sevoflurane. Sevoflurane produced significant dose 
dependent vasodilation of chorionic plate arterial rings compared to control conditions. Prior blockade of KATP channels by 
incubation in 1 × 10-5 M glibenclamide (n = 10 rings per group) enhanced the vasodilatory effect of sevoflurane. *P < 0.05 com-
pared to rings exposed to control conditions. (Two way RM-ANOVA). † P < 0.05 compared to rings exposed to sevoflurane 
plus vehicle at graded sevoflurane concentrations (post hoc between group t test).BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
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It is clear, based on these findings, and those of our prior
study [4], that sevoflurane modulates vasomotor tone in
the foeto-placental circulation via a number of separate
and competing mechanisms. Sevoflurane inhibits the pro-
duction of vasodilator prostanoids, and also inhibits the
activity of the KCa++ and KATP channels, which would act to
increase vascular tone. However, these effects are counter-
balanced by sevoflurane-mediated inhibition of vasocon-
strictor eicosanoid production, and blockade of Ca++
channels, which act to produce vasodilation. The net
effect of these contrasting mechanisms of action is to pro-
duce dose-dependent vasodilation. Of interest, halothane
has been demonstrated to exert similar effects on ion
channel function in isolated smooth muscle cells of
canine cerebral arteries [28], and in canine coronary arte-
rial cells [29]
There are some limitations to this study. Firstly, these
studies are conducted in second order chorionic plate
arteries. Characterisation of the effects of sevoflurane on
smaller vessels in the foeto-placental circulation (i.e. pla-
cental resistance arteries) is also required. Secondly, chor-
ionic plate arterial ring samples were obtained from
healthy parturients. Characterisation of the effects of
sevoflurane in the setting of compromised utero-placental
circulation, in which foetal hypoxia may be more preva-
lent would add further useful information. Thirdly, SK&F
96365, which was utilised to determine the role of the
voltage-independent Ca++  channels in mediating the
vasorelaxant effect of sevoflurane, may also have a weak
VOCC blocking action [9,10]. However, these effects are
only seen at higher concentrations that were used in these
studies, and in any case SK&F 96365 did not modulate the
Blockade of sarcolemmal voltage-operated Ca++ channel (VOCC) attenuates the vasodilatory effect of sevoflurane Figure 6
Blockade of sarcolemmal voltage-operated Ca++ channel (VOCC) attenuates the vasodilatory effect of sevoflu-
rane. Sevoflurane produced significant dose dependent vasodilation of chorionic plate arterial rings compared to control con-
ditions. Prior blockade of VOCC's by incubation in 1 × 10-6 M verapamil (n = 10 rings per group) reduced the vasodilatory 
effect of sevoflurane. *P < 0.05 compared to rings exposed to control conditions. (Two way RM-ANOVA). † P < 0.05 com-
pared to rings exposed to sevoflurane plus verapamil at graded sevoflurane concentrations (post hoc between group t test).BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
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effect of sevoflurane in these studies. Fourthly, our find-
ings may not apply to other inhaled anaesthetic agents,
especially in a quantitative manner. The effects of other
volatile anaesthetics will need to be separately deter-
mined. Fifthly, these experiments were conducted under
conditions of hyperoxia, in contrast to the hypoxic condi-
tions normally experienced by the placental circulation.
Hyperoxia may cause vasoconstriction in this circulation.
However the oxygen levels used in these studies are widely
used in isolated placental vessel preparations [30-32]. Per-
fusate oxygen tensions were the same across all experi-
mental groups in this study. Therefore, the impact of the
oxygen concentrations in these experiments is likely to
have been limited. Finally, there are limitations in extrap-
olating from in vitro experiments to the in vivo situation.
Conclusion
We conclude that sevoflurane dose dependently dilates
the foeto-placental vasculature, by a mechanism mediated
in part via blockade of the voltage-operated calcium chan-
nel, in this isolated placental vessel model. Further study
is required to investigate determine the clinical signifi-
cance of these findings.
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Blockade of sarcolemmal voltage-independent Ca++ channels (VICC), by prior incubation with 1 × 10-4 M SK&F 
96365 (n = 10 rings per group), does not alter sevoflurane mediated vasodilation. Sevoflurane produced significant 
dose dependent vasodilation compared to control conditions, which was not modulated by SK&F 96365. *P < 0.05 compared 
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channels; VOCC: voltage-operated Ca++ channel.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CHM and BDH conceived of the study, and participated
in its design and execution and helped to draft the manu-
script. JJ, and RFF performed experiments, and helped to
draft the manuscript. CDL determined concentrations of
sevoflurane in the perfusate using gas chromatography-
mass spectrometric analyses. NMF and JGL participated in
the design and coordination of the study, performed the
statistical analysis, and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This study was part funded by the Millennium Fund, NUI Galway, Ireland, 
the Yamanouchi European Foundation, and the Health Research Board (Ire-
land). The authors wish to extend their gratitude to the staff of the delivery 
suite at Galway University Hospital, for their help and cooperation in 
obtaining placental tissue.
References
1. Gambling DR, Sharma SK, White PF, Van Beveren T, Bala AS, Gould-
son R: Use of sevoflurane during elective cesarean birth: a
comparison with isoflurane and spinal anesthesia.  Anesth Analg
1995, 81(1):90-95.
2. Chin KJ, Yeo SW: Bispectral index values at sevoflurane con-
centrations of 1% and 1.5% in lower segment cesarean deliv-
ery.  Anesth Analg 2004, 98(4):1140-1144.
3. Chin KJ, Yeo SW: A BIS-guided study of sevoflurane require-
ments for adequate depth of anaesthesia in Caesarean sec-
tion.  Anaesthesia 2004, 59(11):1064-1068.
4. Farragher R, Maharaj CH, Higgins BD, Crowe S, Burke P, Laffey CD,
Flynn NM, Laffey JG: Sevoflurane and the feto-placental vascu-
Blockade of sarcoplasmic reticulum Ca++ channel, by prior incubation with 5 × 10-5 M ryanodine (n = 10 rings per group), does  not alter sevoflurane mediated vasodilation Figure 8
Blockade of sarcoplasmic reticulum Ca++ channel, by prior incubation with 5 × 10-5 M ryanodine (n = 10 rings 
per group), does not alter sevoflurane mediated vasodilation. Sevoflurane produced significant dose dependent 
vasodilation compared to control conditions, which was not modulated by ryanodine. *P < 0.05 compared to rings exposed to 
control conditions. (Two way RM-ANOVA).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Anesthesiology 2009, 9:4 http://www.biomedcentral.com/1471-2253/9/4
Page 11 of 11
(page number not for citation purposes)
lature: the role of nitric oxide and vasoactive eicosanoids.
Anesth Analg 2008, 107(1):171-177.
5. Larach DR, Schuler HG: Potassium channel blockade and
halothane vasodilation in conducting and resistance coro-
nary arteries.  J Pharmacol Exp Ther 1993, 267(1):72-81.
6. Chrissobolis S, Sobey CG: Inwardly rectifying potassium chan-
nels in the regulation of vascular tone.  Curr Drug Targets 2003,
4(4):281-289.
7. Kersten JR, Schmeling T, Tessmer J, Hettrick DA, Pagel PS, Warltier
DC:  Sevoflurane selectively increases coronary collateral
blood flow independent of KATP channels in vivo.  Anesthesiol-
ogy 1999, 90(1):246-256.
8. Kehl F, Krolikowski JG, Tessmer JP, Pagel PS, Warltier DC, Kersten
JR: Increases in coronary collateral blood flow produced by
sevoflurane are mediated by calcium-activated potassium
(BKCa) channels in vivo.  Anesthesiology 2002, 97(3):725-731.
9. Vinh VH, Enoki T, Hirata S, Toda H, Kakuyama M, Nakamura K,
Fukuda K: Comparative contractile effects of halothane and
sevoflurane in rat aorta.  Anesthesiology 2000, 92(1):219-227.
10. Komuro T, Miwa S, Zhang XF, Minowa T, Enoki T, Kobayashi S,
Okamoto Y, Ninomiya H, Sawamura T, Kikuta K, et al.: Physiologi-
cal role of Ca2+-permeable nonselective cation channel in
endothelin-1-induced contraction of rabbit aorta.  J Cardiovasc
Pharmacol 1997, 30(4):504-509.
11. Loughrey JP, Laffey JG, Moore BJ, Lynch F, Boylan JF, McLoughlin P:
Interleukin-1b rapidly inhibits aortic endothelium-depend-
ent relaxation by a DNA transcription-dependent mecha-
nism.  Critical Care Medicine 2003, 31(3):910-5.
12. Fukushima T, Hirasaki A, Jones KA, Warner DO: Halothane and
potassium channels in airway smooth muscle.  Br J Anaesth
1996, 76(6):847-853.
13. Akata T, Izumi K, Nakashima M: The action of sevoflurane on vas-
cular smooth muscle of isolated mesenteric resistance arter-
ies (part 2): mechanisms of endothelium-independent
vasorelaxation.  Anesthesiology 2000, 92(5):1441-1453.
14. Izumi K, Akata T, Takahashi S: The action of sevoflurane on vas-
cular smooth muscle of isolated mesenteric resistance arter-
ies (part 1): role of endothelium.  Anesthesiology 2000,
92(5):1426-1440.
15. Lindauer U, Vogt J, Schuh-Hofer S, Dreier JP, Dirnagl U: Cerebrov-
ascular vasodilation to extraluminal acidosis occurs via com-
bined activation of ATP-sensitive and Ca2+-activated
potassium channels.  J Cereb Blood Flow Metab 2003,
23(10):1227-1238.
16. Nakahata K, Kinoshita H, Hirano Y, Kimoto Y, Iranami H, Hatano Y:
Mild hypercapnia induces vasodilation via adenosine triphos-
phate-sensitive K+ channels in parenchymal microvessels of
the rat cerebral cortex.  Anesthesiology 2003, 99(6):1333-1339.
17. Atalik KE, Kilic M, Nurullahoglu ZU, Dogan N: Effects of cooling on
histamine-induced contractions of human umbilical artery:
the role of ion channels.  Methods Find Exp Clin Pharmacol 2007,
29(9):619-623.
18. Resch BE, Gaspar R, Falkay G: Application of electric field stim-
ulation for investigations of human placental blood vessels.
Obstet Gynecol 2003, 101(2):297-304.
19. Tanaka Y, Imai T, Igarashi T, Takayanagi K, Otsuka K, Yamaki F, Tan-
aka H, Shigenobu K: Comparison of the Ca2+ entry channels
responsible for mechanical responses of guinea-pig aorta to
noradrenaline and thapsigargin using SK&F 96365 and LOE
908.  Naunyn Schmiedebergs Arch Pharmacol 2000, 362(2):160-168.
20. Long W, Zhang L, Longo LD: Cerebral artery sarcoplasmic
reticulum Ca(2+) stores and contractility: changes with
development.  Am J Physiol Regul Integr Comp Physiol 2000,
279(3):R860-873.
21. Pourmahram GE, Snetkov VA, Shaifta Y, Drndarski S, Knock GA, Aar-
onson PI, Ward JP: Constriction of pulmonary artery by perox-
ide: role of Ca(2+) release and PKC.  Free Radic Biol Med 2008,
45(10):1468-76.
22. Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher C: Surgery
during pregnancy and fetal outcome.  Am J Obstet Gynecol 1980,
138(8):1165-1167.
23. Schwarz U, Galinkin JL: Anesthesia for fetal surgery.  Semin Pediatr
Surg 2003, 12(3):196-201.
24. Ducloy-Bouthors AS, Marciniak B, Vaast P, Fayoux P, Houfflin-
Debarge V, Fily A, Rakza T: [Maternal and foetal anaesthesia for
ex utero intrapartum treatment (EXIT) procedure].  Ann Fr
Anesth Reanim 2006, 25(6):638-643.
25. Zorn L, Kulkarni R, Anantharam V, Bayley H, Treistman SN: Haloth-
ane acts on many potassium channels, including a minimal
potassium channel.  Neurosci Lett 1993, 161(1):81-84.
26. Gin T, Chan MT: Decreased minimum alveolar concentration
of isoflurane in pregnant humans.  Anesthesiology 1994,
81(4):829-832.
27. Marijic J, Buljubasic N, Coughlan MG, Kampine JP, Bosnjak ZJ: Effect
of K+ channel blockade with tetraethylammonium on anes-
thetic-induced relaxation in canine cerebral and coronary
arteries.  Anesthesiology 1992, 77(5):948-955.
28. Buljubasic N, Flynn NM, Marijic J, Rusch NJ, Kampine JP, Bosnjak ZJ:
Effects of isoflurane on K+ and Ca2+ conductance in isolated
smooth muscle cells of canine cerebral arteries.  Anesth Analg
1992, 75(4):590-596.
29. Buljubasic N, Rusch NJ, Marijic J, Kampine JP, Bosnjak ZJ: Effects of
halothane and isoflurane on calcium and potassium channel
currents in canine coronary arterial cells.  Anesthesiology 1992,
76(6):990-998.
30. Garcia-Huidobro DN, Garcia-Huidobro MT, Huidobro-Toro JP: Vas-
omotion in human umbilical and placental veins: role of gap
junctions and intracellular calcium reservoirs in their syn-
chronous propagation.  Placenta 2007, 28(4):328-338.
31. Kwek K, Read MA, Khong TY, Bisits AT, Walters WA: Vasoactive
effects of 8-epi-prostaglandin F(2alpha)in isolated human
placental conduit and resistance blood vessels in vitro.  Pla-
centa 2001, 22(6):526-533.
32. Sand AE, Andersson E, Fried G: Effects of nitric oxide donors and
inhibitors of nitric oxide signalling on endothelin- and serot-
onin-induced contractions in human placental arteries.  Acta
Physiol Scand 2002, 174(3):217-223.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2253/9/4/prepub